David Webb (MD DSc FRCP FRSE FFPM(Hon) FMedSci)
Christison Chair of Therapeutics and Clinical Pharmacology
- Centre for Cardiovascular Science
Contact details
- Tel: 0131 242 9216
- Email: D.J.Webb@ed.ac.uk
- Web: My research group
Address
- Street
-
The Queen's Medical Research Institute,
Edinburgh BioQuarter,
47 Little France Crescent - City
- Edinburgh
- Post code
- EH16 4TJ
Research summary
My main clinical interests are in hypertension, chronic kidney disease and cardiovascular risk management and I run a European Society of Hypertension (ESH) Hypertension Excellence Centre in Edinburgh, and coordinate hypertension services in Lothian. My research focuses on the pathophysiology of hypertension and renal disease, particularly arterial stiffness and endothelial function, and includes a large body of work on exploiting the endothelin system for patients with vascular disease. My research spans from studies in animal models of human disease to translational, first-in-human and proof-of-principle studies, and large clinical trials. I am keen to see effective treatments introduced into clinical practice.
-
Circulating argonaute-bound microRNA-126 reports vascular dysfunction and treatment response in acute and chronic kidney disease
In:
iScience
DOI: https://doi.org/10.1016/j.isci.2020.101937
Research output: Contribution to Journal › Article (E-pub ahead of print) -
Multi-layered spatial transcriptomics identify secretory factors promoting hematopoietic stem cell emergence in human development
In:
Cell Stem Cell
Research output: Contribution to Journal › Article (Accepted/In press) -
Deletion of the myeloid endothelin-B receptor confers long-term protection from angiotensin II-mediated renal, retinal & vascular injury
In:
Kidney International
DOI: https://doi.org/10.1016/j.kint.2020.05.042
Research output: Contribution to Journal › Article (Published) -
Chronotherapy in hypertension: the devil is in the details
In:
European Heart Journal, vol. 41, pp. 1606-1607
DOI: https://doi.org/10.1093/eurheartj/ehaa265
Research output: Contribution to Journal › Article (Published) -
Endothelin-1 mediates the systemic and renal hemodynamic effects of GPR81 activation
In:
Hypertension
DOI: https://doi.org/10.1161/HYPERTENSIONAHA.119.14308
Research output: Contribution to Journal › Article (E-pub ahead of print) -
Nonadherence to antihypertensive medications is related to pill burden in apparent treatment-resistant hypertensive individuals
In:
Journal of Hypertension
DOI: https://doi.org/10.1097/HJH.0000000000002398
Research output: Contribution to Journal › Article (E-pub ahead of print) -
The eye, the kidney & cardiovascular disease: old concepts, better tools & new horizons
In:
Kidney International
DOI: https://doi.org/10.1016/j.kint.2020.01.039
Research output: Contribution to Journal › Review article (E-pub ahead of print) -
Established and emerging therapeutic uses of phosphodiesterase type 5 inhibitors in cardiovascular disease
In:
British Journal of Pharmacology
DOI: https://doi.org/10.1111/bph.14920
Research output: Contribution to Journal › Article (E-pub ahead of print) -
Endothelin signalling mediates experience-dependent myelination in the CNS
In:
eLIFE, vol. 8
DOI: https://doi.org/10.7554/eLife.49493
Research output: Contribution to Journal › Article (E-pub ahead of print) -
Pharmacoepidemiology: using randomised control trials and observational studies in clinical decision-making
In:
British Journal of Clinical Pharmacology
DOI: https://doi.org/10.1111/bcp.14024
Research output: Contribution to Journal › Review article (Published) -
Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in Patients With Chronic Kidney Disease
(8 pages)
In:
Hypertension, vol. 74, pp. 323-330
DOI: https://doi.org/10.1161/HYPERTENSIONAHA.119.12919
Research output: Contribution to Journal › Article (Published) -
Renal Denervation Therapy for Hypertension: Still on Trial
In:
Heart
DOI: https://doi.org/10.1136/heartjnl-2019-315255
Research output: Contribution to Journal › Editorial (Published) -
Improving medication safety: focus on prescribers and systems
In:
The Lancet, vol. 394, pp. 283-285
DOI: https://doi.org/10.1016/S0140-6736(19)31526-0
Research output: Contribution to Journal › Comment/debate (Published) -
Endothelin receptor antagonism improves lipid profiles & lowers PCSK9 in patients with chronic kidney disease
In:
Hypertension
DOI: https://doi.org/10.1161/HYPERTENSIONAHA.119.12919.
Research output: Contribution to Journal › Article (Published) -
Retinal fingerprints for precision profiling of cardiovascular risk
In:
Nature Reviews Cardiology
DOI: https://doi.org/10.1038/s41569-019-0205-2
Research output: Contribution to Journal › Article (Published) -
Safety and efficacy of the SNAP 12 hour acetylcysteine regimen for the treatment of paracetamol overdose
In:
EClinicalMedicine
DOI: https://doi.org/10.1016/j.eclinm.2019.04.005
Research output: Contribution to Journal › Article (Published) -
Endothelins in cardiovascular biology and therapeutics
In:
Nature Reviews Cardiology
DOI: https://doi.org/10.1038/s41569-019-0176-3
Research output: Contribution to Journal › Review article (Published) -
A novel role for myeloid endothelin-B receptors in hypertension
In:
European Heart Journal
DOI: https://doi.org/10.1093/eurheartj/ehy881
Research output: Contribution to Journal › Article (Published) -
Impaired Pressure Natriuresis and Non-Dipping Blood Pressure in Rats with Early Type 1 Diabetes Mellitus: Pressure natriuresis and BP in T1DM
In:
Journal of Physiology
DOI: https://doi.org/10.1113/JP277332
Research output: Contribution to Journal › Article (Published) -
The pressure natriuresis response is not affected by SGLT2 inhibition in rats with Type 1 diabetes mellitus
Research output: Contribution to Conference › Poster (Published)